Kamada Ltd. execs said they hope a good secondary endpoint showing from the phase II/III trial in Europe and Canada with its inhaled therapy for alpha-1 antitrypsin (AAT) deficiency – when combined with results from an ongoing phase II study in the U.S. – will impress European regulators enough to grant approval.